Skip to main content

Table 2 The NRI and IDI estimate of NC, NLR and SII

From: Association of inflammatory markers with cerebral small vessel disease in community-based population

Variables

NRI

IDI

Estimate (95% CI), %

P value

Estimate (95% CI), %

P value

Presence of CSVD (Wardlaw)*

    

 Basic model

ref

 

ref

 

 Basic model + NC

13.47 (5.78, 21.16)

 < 0.001

0.22 (0.05, 0.39)

0.01

 Basic model + NLR

9.71 (2.02, 17.41)

0.01

0.05 (-0.03, 0.13)

0.19

 Basic model + SII

5.19 (-2.51, 12.90)

0.19

0.06 (-0.02, 0.14)

0.14

Presence of CSVD (Rothwell)†

    

 Basic model

ref

 

ref

 

 Basic model + NC

13.07 (5.89, 20.25)

 < 0.001

0.14 (0.01, 0.27)

0.03

 Basic model + NLR

7.95 (0.76, 15.15)

0.03

0.04 (-0.03, 0.11)

0.22

 Basic model + SII

6.81 (-0.39, 14.00)

0.06

0.06 (-0.02, 0.15)

0.14

  1. NC neutrophil count, NLR neutrophil-to-lymphocyte ratio, SII systemic immune-inflammation index (platelet count × neutrophil count/lymphocyte count), NRI net reclassification index, IDI integrated discrimination improvement
  2. *Wardlaw: 1 point allocated for presence of lacunes, microbleeds, moderate-to-severe (> 10) perivascular space in basal ganglia, periventricular white matter hyperintensities Fazekas 3 or deep white matter hyperintensities Fazekas 2–3
  3. †Rothwell: 1 point allocated for presence of lacunes, 1–4 microbleeds, frequent to severe (> 20) perivascular space in basal ganglia, moderate white matter hyperintensities (total periventricular + subcortical white matter hyperintensities grade 3–4), 2 points allocated for ≥ 5 microbleeds and severe white matter hyperintensities (total periventricular + subcortical white matter hyperintensities grade 5–6)
  4. Basic model: multivariable logistic regression model included age, sex, body mass index, diabetes, hypertension, total cholesterol, high-density lipoprotein, low-density lipoprotein, fasting blood glucose, homocysteine, previous dyslipidemia, previous heart disease, current smoking, current drinking, previous antiplatelet, anticoagulant, antihypertensive, antidiabetic, lipid-lowing drugs use